Better Dividend Stock: Pfizer Or Merck?

Yahoo Finance’s Ines Ferre joins the Live show to break down how stocks are moving in early trading. Pfizer reported revenues of $25.66 billion in the last reported quarter, representing a year-over-year change of +76%. EPS of $1.62 PFE stock forecast for the same period compares with $0.93 a year ago. Sign Up NowGet this delivered to your inbox, and more info about our products and services. “The countries were not ready to receive vaccines,” he said of the Comirnaty rollout.

Pfizer stock

In addition, PFE reported that in a lab-based setting, Paxlovid had shown a high potential in producing robust anti-viral reactions against the Omicron variant, with additional studies ongoing. Based on its high efficacy rates, on 16 December 2021, the European Medicines Agency has recommended the use of Paxlovid in high-risk patients, even prior to its regulatory approval.

Better Dividend Stock: Pfizer Or Merck?

Even Pfizer’s good news isn’t anything to get overly excited about. It’s unlikely that the EUA for boosters Forex news in young kids will lead to any additional orders of doses of the company’s vaccine over the near term.

Pfizer stock

Pfizer announced Wednesday that it will no longer be making a profit from sales of its drugs to low-income countries. Receive a free world-class investing education from MarketBeat.

Earnings & Revenue

PFE’s dividend (2.96%) is low compared to the top 25% of dividend payers in the US market (4.01%). PFE’s dividend (2.96%) is higher than the bottom 25% of dividend payers in the US market (1.54%). PFE’s revenue is forecast to decline over the next 3 years (-13.3% per year).

  • It looks to continue growing throughout the rest of the decade despite losing exclusivity for several key drugs.
  • Depending on the Covid-19 vaccine or pill will not help the company in the long term, however, this is not the stock you should write off.
  • The company’s average rating score is 2.47, and is based on 9 buy ratings, 10 hold ratings, and no sell ratings.
  • From this point, Pfizer stock trended gradually downward, closing in a slightly below average area under the 20-day moving average.
  • Still, Pfizer expects to increase its revenue by a compound annual growth rate of at least 6% through 2025 excluding its COVID-19 programs altogether.

However, as coronavirus cases are on a decline globally, it raises concerns over the future of vaccine makers. ATR is a standard tool for illustrating historical volatility over time. These bands could be considered to represent the extreme ranges of option pricing. An analysis of recent option activity combined with technical analysis of share price movement can help chart watchers gain valuable insight into the overall sentiment toward Forex news. The chart below depicts the recent price action for the Pfizer share price as of Thursday, Feb. 10.

Leave a Reply

Your email address will not be published. Required fields are marked *

Connect With Us

Give us a call or fill in the form below and we will contact you. We endeavour to answer all inquiries within 24 hours on business days.